Philip Reid

IAGS (International Andreas Gruentzig Society) Proceedings

Industry Round Table: Where Are the New Drugs? (IAGS 2004)

08/01/2008

Philip Reid (Eli Lilly & Company): Speaking as a cardiologist, not as a neurologist, I find that the challenge with the trial that Renato has just described is to demonstrate the efficacy of abciximab in acute nonhemorrhagic stroke patients....

Philip Reid (Eli Lilly &...

08/01/2008

Journal of Invasive Cardiology

IAGS (International Andreas Gruentzig Society) Proceedings

Microvascular Disease and Injury: Prevention and Therapies

08/01/2008

Pierre Leimgruber , MD;

Jeffrey Werner , MD;

Philip Reid ;

Kenneth M. Kent , MD, PhD;

Richard R. Heuser , MD, FACC, FACP, FESC, FSCAI;

Jorge A. Belardi , MD, PhD;

Howard A. Cohen , MD;

Tim Fischell: Many centers have spent a lot of money on the 25 or so different distal protection devices available today. We are currently preparing a manuscript on a slightly different, simpler, and considerably less expensive approach to...

Tim Fischell: Many centers have...

08/01/2008

Journal of Invasive Cardiology